What the End of Aduhelm Means for Alzheimer's Drugs

Biogen announc Nick Blackmer i Key Takeaways e Biogen Aduhelm, a controversial monoclonal antibody drug for Alzheimer’s disease.

Biogen will continue to Aduhelm a Aduhelm ent medic first , called Leqembi, that it manufactures with pharmaceutical company Eisai.

The drug will leave the market in November 2024 Aduhelm heimer's Association credits Aduhelm with generating interest and advancement in Alzheimer’s drug research.

More d Biotech e in the Biogen ne for the last week ; a Lilly medication c Aduhelm onanemab is under FDA review now.

Patients should meet with their doctor to discuss alternatives or November 2024 ls Aduhelm class="summa monthly h IV hLightText__NxlGi">Verywell Health the Food and Drug Administration ex FDA Nx just three years ago Aduhelm FDA LillyAccelerated class="summaryFeed_highLightText__NxlGi">the Alzheimer’s Association Aduhelm LeqembiAduhelm Biogen ass="summaryFeed_highLightText__NxlGi">Gordon V Accelerated an> Gordon Biogen yFeed_highLightText__NxlGi">New York Aduhelm Glen Oaks Zucker Hillside Ho 28,000 < annual MD Marc L. Gordon the Alzheimer’s Association Aduhelm >Aduhelm Medicare a few months later FDA Aduhelm Being Discontinued xlGi">la Aduhelm two ghLightTe Biogen lGi">LeqembiFDA two Leqembi Anastasiya Shor ogen the Drug Information Center at _ Touro College of Pharmacy cla New York aryFeed Verywell htText__NxlGi">Aduhelm PET Leqembi Aduhelm Shor t__NxlGi">Leqembi < Medicare ss="summaryFeed_hig Aduhelm ext__NxlGi">Leqembi Aduhelm Leqembi Eisai Leqembi Biogen